Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Nintedanib in Progressive Pneumoconiosis Study
NCT04161014Phase 2Unknown
- Sponsor
- Holdsworth House Medical Practice
- Start
- Oct 2020
- Primary completion
- Dec 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of nintedanib in pneumoconiosis, asbestosis, silicosis, coal workers' pneumoconiosis (CWP), sponsored by Holdsworth House Medical Practice. Status: unknown.
02
Drugs
nintedanib
03
Conditions
pneumoconiosisasbestosissilicosiscoal workers' pneumoconiosis (CWP)
Beyond the preview
Go deeper on NCT04161014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04161014.